{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-23-000006","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.724766+00:00","generated_at":"2026-06-18T00:20:59.010497+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"SELLAS Life Sciences reports FY2022 net loss $41.3M; cash $17.1M, raised $20M in Feb 2023 plus $13M milestone expected","bullets":["Net loss $41.3M ($2.13 per share) vs $20.7M loss ($1.34 per share) in 2021.","Cash $17.1M at Dec 31, 2022; subsequent $20M public offering gross proceeds in Feb 2023.","Phase 3 REGAL AML study interim analysis expected late 2023/early 2024.","$13M milestone payment from 3D Medicines expected in H1 2023.","Phase 1 of CDK9 inhibitor GFH009 shows no dose-limiting toxicities; first confirmed CR in AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-23-000006","json":"https://secwatch.observer/filing/0001390478-23-000006.json","markdown":"https://secwatch.observer/filing/0001390478-23-000006.md","text":"https://secwatch.observer/filing/0001390478-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/0001390478-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/sls-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:20:59.010497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f10a4aa8b941309c3404134da6e8439f3b9b0d83","claim":"SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 16, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2022 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/0001390478-23-000006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}